Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. AKTX
AKTX logo

AKTX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AKTX News

Akari Therapeutics Appoints New Scientific Advisor to Advance AKTX-101

Feb 26 2026Newsfilter

Akari Therapeutics to Present at Biocom Global Partnering Conference

Feb 18 2026Newsfilter

Akari Therapeutics Highlights 2025 Progress, Plans First-in-Human Trials in 2026

Jan 09 2026Globenewswire

Akari Therapeutics Presents ADC Platform and 2026 Strategic Priorities at Biotech Showcase

Jan 08 2026Globenewswire

Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%

Dec 31 2025Benzinga

Akari Therapeutics Advances Novel Antibody Drug Conjugates with Significant Achievements in 2025

Dec 30 2025Newsfilter

Akari Therapeutics Highlights 2025 Progress and Future Plans

Dec 30 2025Globenewswire

Akari Initiates GMP Manufacturing for AKTX-101 Antibody-Drug Conjugate

Dec 24 2025NASDAQ.COM

Akari Therapeutics Issues 12.6M ADSs Raising $5M for Oncology Development

Dec 16 2025Newsfilter

Akari Therapeutics Advances Novel ADCs, Plans Clinical Trials for AKTX-101 in Q4 2026

Dec 04 2025Globenewswire

Akari Therapeutics Names Kameel D. Farag as Interim CFO, Bringing Biotech Finance Expertise

Nov 18 2025Newsfilter

Teradata Shares Surge Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

Nov 05 2025Benzinga

Akari Therapeutics' Accepted Abstract Highlights Innovative Splicing-Targeted ADC Payload That Promotes Immune Activation

Nov 04 2025Newsfilter

Akari Therapeutics Establishes Scientific Advisory Board and Welcomes Esteemed Medical Oncologist Sara A. Hurvitz, MD, FACP, as First Member

Oct 30 2025Newsfilter

Akari Therapeutics Unveils New CEO Corner Platform

Oct 22 2025Newsfilter

Akari Therapeutics Submits Two New Patents for Immuno-Oncology Mechanism of Action in Innovative ADC Platform Featuring Spliceosome Modulating Payload PH1

Oct 09 2025Newsfilter